Given the association between ALT and ATRX loss-of-function mutations, and the role of ATRX in intrinsic resistance to viral infection, we examined whether this difference between healthy cells and ALT tumor cells creates a vulnerability in ALT cancers that could be exploited for synthetic lethality. The gene discussed is ATRX; the disease is cancer.